title: Effect of oral coenzyme Q10 supplementation on the oxidation resistance of human VLDL+LDL fraction: absorption and antioxidative properties of oil and granule-based preparations.
abstract: Coenzyme Q10 (Q10) is supposed to be an important endogenous lipid-soluble antioxidant. We studied 60 healthy 46 +/- 7 (mean +/- SD)-year-old smoking men. They were randomized into three groups to receive oil-based or granular Q10 (90 mg/d) or placebo for 2 months. Oil-based capsule elevated Q10 in plasma by 178% and in VLDL+LDL fraction by 160%. The granular preparation increased Q10 in plasma by 168% and in VLDL+LDL by 127%. However, the 2-month Q10 supplementation did not increase the oxidation resistance of VLDL+LDL fraction, as assessed by copper induced VLDL+LDL oxidation, haemin+H(2)O(2)-induced VLDL+LDL oxidation, total antioxidative capacity of LDL, and plasma malondialdehyde measurements. The first and the last dose was used to carry out a 12 h pharmacokinetic study (five subjects per group), which indicated that only a small part of supplemented Q10 was absorbed to the circulation in 12 h and that the absorption varied extensively between subjects. Our results suggest that at least among smoking men, 90 mg of orally supplemented Q10 daily does not increase the oxidation resistance of VLDL+LDL. Bioavailability of both the granular and the oil-based Q10 preparation was similar during the long-term supplementation, but one dose of 30 mg had only a marginal effect on the plasma levels of Q10.
authors.affiliation: Research Institute of Public Health, University of Kuopio, Finland.
authors.forename: J
authors.initials: J
authors.lastname: Kaikkonen
authors.forename: K
authors.initials: K
authors.lastname: Nyyssönen
authors.forename: E
authors.initials: E
authors.lastname: Porkkala-Sarataho
authors.forename: H E
authors.initials: HE
authors.lastname: Poulsen
authors.forename: T
authors.initials: T
authors.lastname: Metsä-Ketelä
authors.forename: M
authors.initials: M
authors.lastname: Hayn
authors.forename: R
authors.initials: R
authors.lastname: Salonen
authors.forename: J T
authors.initials: JT
authors.lastname: Salonen
mesh_terms: D000284:Administration, Oral; D001682:Biological Availability; D003067:Coenzymes; D003300:Copper / Q000494:pharmacology; D004042:Dietary Fats, Unsaturated / Q000008:administration & dosage / Q000494:pharmacology; D006801:Humans; D007408:Intestinal Absorption; D015227:Lipid Peroxidation / Q000187:drug effects*; D008077:Lipoproteins, LDL / Q000097:blood / Q000378:metabolism*; D008079:Lipoproteins, VLDL / Q000097:blood / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D014451:Ubiquinone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology
chemical_list: D003067:Coenzymes; D004042:Dietary Fats, Unsaturated; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D014451:Ubiquinone; D003300:Copper; C024989:coenzyme Q10